Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Sho FurusawaHiroshi NomotoHiroki YokoyamaYuka SuzukiAtsushi TsuzukiKiyohiko TakahashiAika MiyaHiraku KamedaKyu Yong ChoJun TakeuchiSo NagaiShinji TanedaYoshio KuriharaAkinobu NakamuraTatsuya Atsuminull nullPublished in: Diabetes, obesity & metabolism (2023)
Although the potential for gastrointestinal symptoms should be carefully considered, switching from DPP-4is to oral semaglutide may be beneficial for glycaemic control and metabolic abnormalities in people with higher HbA1c and insulin resistance.
Keyphrases
- open label
- type diabetes
- insulin resistance
- double blind
- clinical trial
- phase iii
- phase ii
- study protocol
- adipose tissue
- phase ii study
- placebo controlled
- metabolic syndrome
- high fat diet
- randomized controlled trial
- polycystic ovary syndrome
- squamous cell carcinoma
- risk assessment
- cross sectional
- sleep quality
- high fat diet induced
- rectal cancer